P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. The Lancet , 2014; DOI: 10.1016/S0140-6736(14)61255-1 Cite This Page : ...

A novel P2X3 receptor antagonist, in multiple doses up to 750 mg, was well tolerated, and higher doses significantly reduced cough count and severity compared with placebo in patients with ...

In recent years, several P2X3 antagonists have been explored for their potential to treat chronic cough, including gefapixant (Merck) and eliapixant (Bayer). This specific study has trialed the ...

Smith J, Morice AH, Birring SS, et al. Improvements in cough frequency over 24 hours with BLU-5937, a selective P2X3 antagonist, in patient subgroups defined by baseline awake cough frequencies ...

MILAN -- Twice-daily doses of the oral P2X3 receptor antagonist gefapixant may improve refractory or unexplained chronic cough, but at the cost of adverse events, a meta-analysis and systematic ...

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended ...

That side effect was the most common one reported in mid-stage clinical testing of Merck’s P2X3-targeting cough drug, gefapixant. The FDA rejected that drug last year, asking for more ...

FDA issues a second complete response letter to MSD's gefapixant for chronic cough, ... The P2X3 blocker class has however proved to be challenging for drug developers.

Recent findings suggest that post-COVID chronic cough may be driven by neurologic factors, not just respiratory issues. ... These receptors, such as P2X2, P2X3, and others, ...

The acquisition provides GSK access to Camlipixant, a P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.